|
Agammaglobulinemia
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus.
|
29114388 |
2017 |
|
Agammaglobulinemia
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Agammaglobulinemia
|
0.600 |
Biomarker
|
disease |
HPO |
|
|
|
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
BEFREE |
Strikingly, we did not detect recurrent mutations in genes of the ID3-TCF3 axis or the SWI/SNF complex that are frequently altered in BL, or in genes frequently mutated in germinal center-derived B-cell lymphomas like <i>KMT2D</i> or <i>CREBBP</i> An exception is <i>GNA13</i>, which was mutated in 7 of 15 cases.
|
30567752 |
2019 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
BEFREE |
A total of four TFs (E2F1, NFKB1, E2F4 and TCF3) exhibit complicated regulation associations in BL-associated networks.
|
30127896 |
2018 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
BEFREE |
In conclusion, <i>ID3-TCF3-CCND3</i> pathway genes are mutated in more than 88% of <i>MYC</i>-rearranged pediatric B-cell non-Hodgkin lymphoma and the pathway may represent a highly relevant second hit of Burkitt lymphoma pathogenesis, especially in children and adolescents.
|
28209658 |
2017 |
|
Burkitt Lymphoma
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
Since no definitive data are available on the genetic landscape of endemic Burkitt (eBL), we first assessed the mutation frequency of TCF3/ID3 in eBL compared with sBL and subsequently the somatic hypermutation status of the BCR to answer whether an extrinsic activation of BCR signaling could also be demonstrated in Burkitt lymphoma.
|
26712879 |
2016 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
BEFREE |
TCF-3 promotes antigen-independent (tonic) B-cell-receptor signaling in Burkitt lymphoma by transactivating immunoglobulin heavy- and light-chain genes while repressing PTPN6, which encodes the phosphatase SHP-1, a negative regulator of B-cell-receptor signaling.
|
24492847 |
2014 |
|
Burkitt Lymphoma
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
In particular, mutations in the transcription factors ID3 and TCF3, leading to overexpression of B-cell receptor components such as VPREB3, have been shown to be specific for Burkitt lymphoma (BL) and play an important tumourigenic role by mediating the activation of the pro-survival phosphatidylinositol-3-OH kinase pathway.
|
24493312 |
2014 |
|
Burkitt Lymphoma
|
0.580 |
GeneticVariation
|
disease |
BEFREE |
Two studies in this issue identify the landscape of somatic mutations in Burkitt lymphoma and highlight the pathogenic and clinical relevance of inactivating mutations of ID3, an inhibitor of the TCF3 transcription factor.
|
23192177 |
2012 |
|
Burkitt Lymphoma
|
0.580 |
AlteredExpression
|
disease |
BEFREE |
TCF3 activated the pro-survival phosphatidylinositol-3-OH kinase pathway in BL, in part by augmenting tonic B-cell receptor signalling.
|
22885699 |
2012 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
CTD_human |
B-cell development fails in the absence of the Pbx1 proto-oncogene.
|
17244677 |
2007 |
|
Burkitt Lymphoma
|
0.580 |
Biomarker
|
disease |
CTD_human |
Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor.
|
1967982 |
1990 |
|
Burkitt Lymphoma
|
0.580 |
FusionGene
|
disease |
ORPHANET |
|
|
|
|
Childhood Acute Lymphoblastic Leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The <i>ERG</i> risk genotype was underrepresented in ALL with the <i>ETV6-RUNX1</i> fusion (<i>P</i> < .0005) but enriched in the <i>TCF3-PBX1</i> subtype (<i>P</i> < .05).
|
30510082 |
2019 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
t(17;19)(q21-q22;p13), responsible for TCF3-HLF fusion, is a rare translocation in childhood B-cell precursor acute lymphoblastic leukemia(BCP-ALL). t(1;19)(q23;p13), producing TCF3-PBX1 fusion, is a common translocation in childhood BCP-ALL.
|
31305009 |
2019 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine whether methylation differences between mostly fatal TCF3-HLF and curable TCF3-PBX1 pediatric acute lymphoblastic leukemia subtypes can be associated with differential gene expression and remission.
|
29334255 |
2018 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan.
|
28436581 |
2017 |
|
AGAMMAGLOBULINEMIA 8, AUTOSOMAL DOMINANT
|
0.400 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus.
|
29114388 |
2017 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We reviewed the roles of miRNA here with emphasis on their function in human leukemia and the mechanisms of the TEL/AML1, BCR/ABL, MLL/AF4 and TCF3/PBX1 oncoproteins on miRNAs expression in acute lymphoblastic leukemia.
|
27431573 |
2016 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in clinical development.
|
26214592 |
2015 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in clinical development.
|
26214592 |
2015 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol.
|
25551271 |
2015 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Investigation for TCF3(E2A)-PBX1 rearrangements may be useful in BCL6-positive B-lymphoblastic leukemia.
|
25780007 |
2015 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
|
26214592 |
2015 |